Fig.7From: Cellular hierarchy framework based on single-cell/multi-patient sample sequencing reveals metabolic biomarker PYGL as a therapeutic target for HNSCCGSH metabolism correlated with PYGL-mediated glycogen degradation and poor prognosis. A GSVA between PYGL-low and PYGL-high group. B Correlation analysis between glycogen degradation and GSH metabolism. C Consensus map for NMF clustering. D Kaplan–Meier curves for survival probability of the two clusters. E The result of PAS and 2-NBDG assay in PYGL knock-down groups (n = 5). F Glycogen accumulation in PYGL knock-down groups was detected by standardized PAS staining. G The level of GSH and ROS in PYGL knock-down groups (n = 5). H ROS level was measured by ROS detection in PYGL knock-down groupsBack to article page